Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 15/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8365625 | 0.88 | ABCB1 (0.46) | CASP1SLC1A3SLC1A2SLC1A1CA1 | |
| SCHEMBL6671273 | 0.84 | SLC1A3 (0.57) | SLC1A3SLC1A2SLC1A1CA1CA2 | |
| SCHEMBL6671271 | 0.84 | SLC1A3 (0.57) | SLC1A3SLC1A2SLC1A1CA1CA2 | |
| SCHEMBL18775042 | 0.84 | CTSK (0.52) | CA2CA12CA9 | |
| SCHEMBL28367643 | 0.84 | CTSK (0.52) | CA2CA12CA9 | |
| SCHEMBL6752720 | 0.83 | CASP1 (0.49) | CASP1CA1CA2CA12CA9 | |
| SCHEMBL10058309 | 0.82 | SLC1A3 (0.50) | CASP1SLC1A3SLC1A2SLC1A1CA1 | |
| SCHEMBL5019111 | 0.78 | ALDH1A1 (0.51) | CASP1 | |
| SCHEMBL27561390 | 0.78 | CASP1 (0.51) | CASP1 | |
| SCHEMBL7380824 | 0.77 | CASP1 (0.81) | CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655399-B1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-8497245-B2 | Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors IIa and Xa | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20120252743-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2012083436-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252743-A1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, THEIR PREPARATION AND USE AS SELECTIVE INHIBITORS OF THE CLOTTING FACTORS IIA AND XA | F2, F12, SERPINC1 | CASP1 561/4885SLC1A3 4139/4885SLC1A2 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.